; (B) consider the annual threat-based review and reports referenced in and input received under subsection (a)(7); and (C) consult with experts in medication production, distribution, and demand, including economists or other analysts with expertise in the economic factors affecting domestic and foreign production and distribution of critical medications. (6) Incorporation of findings and determinations in submissions to Congress With respect to each designated critical medication, the Assistant Secretary for Preparedness and Response shall include in the annual coordinated 5-year budget plan required to be submitted under section 2811(b)(7) such amounts as are determined to be necessary or appropriate to fund the procurement or contracting required under subsection (c) for such designated critical medications. (c) Procurement or contracting for designated critical medications To ensure availability in the event of a public health emergency Subject to the availability of appropriations, the Secretary shall procure for the Strategic National Stockpile pursuant to section 319F–2(a)(1)(A)(ii), or otherwise enter into contracts under such section, as necessary to ensure the availability of each designated critical medication, in the quantities and at the times needed, in the event of a public health emergency. (d) Evaluating impediments to domestic production of critical medications, and related recommendations (1) Report to Congress Not later than one year after the date of enactment of this section, the Secretary shall make available to the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives and the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate, a report containing— (A) findings on— (i) the domestic and foreign production of critical medications and their key ingredients; and (ii) impediments to the domestic production of critical medications and their key ingredients